Merve Celik Guler

Merve Celik Guler

Auto-generated profile, based on publicly available information

Merve Celik Guler

Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI 48109

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
OBOzge Besci
Ozge Besci
MFMaria Cristina Foss-Freitas
Maria Cristina Foss-Freitas
NGNatalia Rossin Guidorizzi
Natalia Rossin Guidorizzi
MGMerve Celik Guler
Merve Celik Guler
DGDonatella Gilio
Donatella Gilio
EOElif A Oral
Elif A Oral
Context Lipodystrophy syndromes are a heterogeneous group of rare genetic or acquired disorders characterized by generalized or partial loss of adipose tissue. LMNA-related lipodystrophy syndromes are classified based on the severity and distribution of adipose tissue loss. Objective We aimed to annotate all clinical and metabolic features of patients with lipodystrophy syndromes carrying pathogenic LMNA variants and assess potential genotype-phenotype relationships. Methods We retrospectively reviewed and analyzed all our cases (n=115) and all published cases (n=379) curated from 94 studies in the literature. Results The study included 494 patients. The most common variants in our study, R482Q and R482W, were associated with similar metabolic characteristics and complications though those with the R482W variant were younger (33 (24) years vs 44 (25) years, p<0.001), had an earlier diabetes diagnosis, (27 (18) vs 40 (17) years, p<0.001) and had lower BMI levels (24 (5) kg/m2 vs 25 (4) kg/m2, p=0.037). Dyslipidemia was the earliest biochemical evidence described in 83% of all patients at a median age of 26 (10) years, while diabetes was reported in 61% of cases. Among 39 patients with an episode of acute pancreatitis, the median age at acute pancreatitis diagnosis was 20 (17) years. Patients who were reported to have diabetes had 3.2 times, while those with hypertriglyceridemia had 12.0 times, the odds of having pancreatitis compared to those who did not. Conclusion This study reports the largest number of patients with LMNA-related lipodystrophy syndromes to date. Our report helps to quantify the prevalence of the known and rare complications associated with different phenotypes and serves as a comprehensive catalog of all known cases.

11 April 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
ISILGIN YILDIRIM SIMSIR
ILGIN YILDIRIM SIMSIR
BTBeyhan Tüysüz
Beyhan Tüysüz
MOMehmet Nuri Ozbek
Mehmet Nuri Ozbek
STSeher Tanrikulu
Seher Tanrikulu
MGMerve Celik Guler
Merve Celik Guler
BABaris Akinci
Baris Akinci
Aim: To describe the Turkish generalized lipodystrophy (GL) cohort with the frequency of each complication and the death rate during the period of the follow‐up. Methods: This study reports on 72 patients with GL (47 families) registered at different centres in Turkey that cover all regions of the country. The mean ± SD follow‐up was 86 ± 78 months. Results: The Kaplan–Meier estimate of the median time to diagnosis of diabetes and/or prediabetes was 16 years. Hyperglycaemia was not controlled in 37 of 45 patients (82.2%) with diabetes. Hypertriglyceridaemia developed in 65 patients (90.3%). The Kaplan–Meier estimate of the median time to diagnosis of hypertriglyceridaemia was 14 years. Hypertriglyceridaemia was severe (≥ 500 mg/dl) in 38 patients (52.8%). Seven (9.7%) patients suffered from pancreatitis. The Kaplan–Meier estimate of the median time to diagnosis of hepatic steatosis was 15 years. Liver disease progressed to cirrhosis in nine patients (12.5%). Liver disease was more severe in congenital lipodystrophy type 2 (CGL2). Proteinuric chronic kidney disease (CKD) developed in 32 patients (44.4%) and cardiac disease in 23 patients (31.9%). Kaplan–Meier estimates of the median time to diagnosis of CKD and cardiac disease were 25 and 45 years, respectively. Females appeared to have a more severe metabolic disease, with an earlier onset of metabolic abnormalities. Ten patients died during the follow‐up period. Causes of death were end‐stage renal disease, sepsis (because of recurrent intestinal perforations, coronavirus disease, diabetic foot infection and following coronary artery bypass graft surgery), myocardial infarction, heart failure because of dilated cardiomyopathy, stroke, liver complications and angiosarcoma. Conclusions: Standard treatment approaches have only a limited impact and do not prevent the development of severe metabolic abnormalities and early onset of organ complications in GL.

1 November 2021 in La Presse Médicale
Verified
Journal Article
Closed access
GAGulcin Akinci
Gulcin Akinci
MCMerve Celik
Merve Celik
BABaris Akinci
Baris Akinci

2 November 2025 in Expert Review of Endocrinology & Metabolism
Verified
Journal Article
Closed access
OBOzge Besci
Ozge Besci
MGMerve Celik Guler
Merve Celik Guler
MFMaria Cristina Foss-Freitas
Maria Cristina Foss-Freitas
EOElif Arioglu Oral
Elif Arioglu Oral
Lipodystrophy syndromes are a heterogeneous group of rare disorders characterized by partial or generalized loss of adipose tissue, which may be either inherited or acquired. Loss of adipose tissue in typical storage sites starting from birth or later in life, combined with abnormal fat accumulation in other organs, contributes to multiple metabolic complications. There is currently no definitive cure available for lipodystrophy syndromes, and clinical management remains symptomatic. For this review, available databases were searched to identify publications and studies on current and emerging therapies to discuss the management of lipodystrophy syndromes. Dietary modification, exercise, lifestyle management, and metreleptin therapy are the mainstay of treatment, while conventional therapies are used to target specific complications. Novel interventions are under investigation to address unmet clinical needs. There is currently no cure for lipodystrophy syndromes. Emerging therapies are being investigated to expand therapeutic options and improve long-term outcomes of this complex disorder.

16 July 2025 in Clinical Endocrinology
Verified
Journal Article
Open access
DGDonatella Gilio
Donatella Gilio
OBOzge Besci
Ozge Besci
NGNatália Rossin Guidorizzi
Natália Rossin Guidorizzi
MGMerve Celik Guler
Merve Celik Guler
ISIlgin Yildirim Simsir
Ilgin Yildirim Simsir
EOElif A. Oral
Elif A. Oral
Context: Familial partial lipodystrophy type 2 (FPLD2) is a rare autosomal dominant disorder caused by pathogenic variants in the LMNA gene. The influence of parental inheritance on clinical presentation has not been fully explored.Objective: To investigate the influence of maternal versus paternal inheritance of LMNA variants on the clinical and metabolic phenotype of patients with FPLD2.Design, Patients, Measurements: This retrospective cohort study included 83 patients with FPLD2 from four different centres. Clinical, biochemical, and body composition data were analysed. Patients were grouped based on maternal (maternal inheritance group; n = 49) or paternal (paternal inheritance group; n = 34) inheritance of LMNA variants. Statistical comparisons were made between the groups.Results: Patients in the maternal inheritance group had a younger current age (35 (33) vs. 48 (22) years, p = 0.042) and earlier diagnosis of lipodystrophy (22 (30) vs. 36 (25) years, p = 0.044) compared to those in the paternal inheritance group. Body fat percentages in the arms (23.8 (6.5) % vs. 21.0 (6.2) %, p = 0.034) and trunk (32.1 (10.3) % vs. 28.5 (6.1) %, p = 0.024) were higher in maternal inheritance group. Fatty liver disease (79% vs. 57%, p = 0.029) and pancreatitis (26% vs. 8%, p = 0.033) were more prevalent in paternal inheritance group.Conclusion: Parental lineage may influence the phenotype of FPLD2: patients with a maternally inherited LMNA variant tend to preserve more adipose tissue in the upper body, while those with a paternally inherited variant experience greater adipose tissue loss in that region, often associated with more severe metabolic complications. These findings highlight the importance of contemplating parental lineage as a relevant factor when evaluating the clinical presentation and management of patients with FPLD2.

12 March 2024 in Rheumatology Quarterly
Verified
Journal Article
Closed access
SGSemih Gülle
Semih Gülle
MGMerve Çelik Güler
Merve Çelik Güler
DGDuygu Gürel
Duygu Gürel
FÖFatoş Önen
Fatoş Önen
Cogan’s syndrome (CS) is a rare chronic autoimmune vasculitis that can have significant systemic consequences and progress with progressive and inflammatory eye (interstitial keratitis, scleritis, episcleritis, uveitis) and audiovestibular (sensorineural hearing loss, vertigo, tinnitus) involvement. Vasculitis is observed in approximately 15% of patients with CS and may present as aortitis, large-vessel vasculitis (Takayasu-like), moderate arteritis, or other vasculitic syndromes. In this case report, we present the development of severe aortic and mitral valve insufficiency in a patient diagnosed with CS who was admitted to the hospital with episcleritis and sensorineural hearing loss.